Pancreatic Cancer: Clinical Trials

823 completed, 322 unknown, 281 recruiting, 237 terminated. 678 Phase 2, 550 Phase 1, 349 Not applicable, 122 Phase 3, 52 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	678	Completed 308, Terminated 106, Unknown 85, Recruiting 73, Active not recruiting 38, Not yet recruiting 36, Withdrawn 25, Suspended 6, Enrolling by invitation 1
Phase 1	550	Completed 245, Terminated 94, Recruiting 68, Unknown 56, Active not recruiting 33, Withdrawn 27, Not yet recruiting 20, Suspended 7
Not applicable	349	Completed 120, Unknown 73, Recruiting 65, Terminated 29, Not yet recruiting 27, Withdrawn 17, Active not recruiting 16, Suspended 2
Phase 3	122	Completed 54, Unknown 21, Recruiting 16, Terminated 15, Not yet recruiting 8, Active not recruiting 4, Withdrawn 4
Early Phase 1	52	Recruiting 12, Unknown 10, Terminated 9, Completed 8, Not yet recruiting 6, Withdrawn 4, Active not recruiting 3
Phase 4	25	Completed 12, Unknown 4, Terminated 3, Not yet recruiting 2, Recruiting 2, Active not recruiting 1, Withdrawn 1

Follow Pancreatic Cancer: new trials by email Literature Review of Pancreatic Cancer trials Research Report on Pancreatic Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC Rintatolimod - Pancreatic Cancer	Phase 2	Suspended	AIM ImmunoTech Inc.	90	2027-08-01	2026-08-19
Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation DN022150+AG( Stage I ）, DN022150+AG（Stage II）, placebo+AG（Stage II） - Pancreatic Cancer, Pancreatic Carcinoma	Phase 2 / Phase 3	Not yet recruiting	Jiangxi Kvvit Pharmaceutical Co., Ltd.	465	2027-06-06	2026-06-18
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer EF-009 - Pancreatic Cancer	Phase 1 / Phase 2	Not yet recruiting	Everfront Biotech Co., Ltd.	30	2027-04-01	2026-09-11
Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity blood sampling - Pancreatic Cancer		Not yet recruiting	Institut Paoli-Calmettes	310	2027-01-04	2026-09-18
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer	Phase 1 / Phase 2	Not yet recruiting	LG Chem	250	2026-12-01	2026-08-07
Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer H101, Camrelizumab - Pancreatic Cancer	Phase 2	Not yet recruiting	Fudan University	30	2026-12-01	2025-08-07
Trial of First-line Gemcitabine and Nab-paclitaxel With or Without L-glutamine in Advanced Pancreatic Cancer Gemcitabine (1000 mg/m2), Nab-paclitaxel, L-glutamine - Pancreatic Cancer	Phase 2	Not yet recruiting	Jun Gong, MD	200	2026-12-01	2026-10-08
Personalised Nutritional Care in Older Patients With Pancreatic Ductal Adenocarcinoma Experimental: Personalised nutritional care delivered by a trained dietitian - Pancreatic Cancer	Not applicable	Not yet recruiting	Inna Chen, MD	250	2026-11-01	2026-09-16
Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) SPLP, LPS - Pancreatic Cancer, Pancreatectomy	Not applicable	Not yet recruiting	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	360	2026-11-01	2026-09-02
Pancreatic Cancer Lifestyle Evolution And Resistance Endoscopic Ultrasound with FNA/FNB - Pancreatic Cancer		Not yet recruiting	IRCCS San Raffaele	150	2026-10-31	2026-08-31
A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic Cancer SKB571 - Pancreatic Cancer	Phase 2	Not yet recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	30	2026-10-31	2026-09-10
Endoscopic Management of Biliopancreatic Disease in the Lombardy Pancreas Units Pancreatic Cancer, Biliopancreatic Diseases		Not yet recruiting	IRCCS San Raffaele	2500	2026-10-31	2026-09-03
PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA Lm-LLO-TT - Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer	Phase 1	Not yet recruiting	Loki Therapeutics, Inc.	18	2026-10-15	2026-09-18
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer GLP1-RA (semaglutide) - Pancreatic Cancer, Colorectal Cancer	Early Phase 1	Recruiting	University of Arizona	30	2026-10-10	2026-09-18
Diagnostic Utility of Protein Biomarkers in Pancreatic Ductal Adenocarcinoma Blood-Based Protein Biomarker Assessment - Pancreatic Cancer, Chronic Pancreatitis		Recruiting	Grigore T. Popa University of Medicine and Pharmacy	100	2026-10-08	2026-10-19
Molecularly Tailored Therapy in Advanced Pancreatic Cancer Arm 1: Molecularly Tailored Therapy, Arms 2: Standard-of-Care Therapy, Arm 3: Standard-of-Care Observational Cohort - Pancreatic Cancer	Phase 2	Not yet recruiting	Herlev Hospital	1200	2026-10-01	2026-09-03
Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer Corsano CardioWatch, Prehab4Cancer Programme - Pancreatic Cancer, Pancreatic Neoplasms	Not applicable	Not yet recruiting	Manchester University NHS Foundation Trust	120	2026-10-01	2026-08-19
Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma Avutometinib (VS-6766) + Defactinib (VS-6063) - Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 1 / Phase 2	Not yet recruiting	University of Virginia	31	2026-10-01	2026-09-17
Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation Fludarabine, Cyclophosphamide, NW-301V - Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)	Phase 1	Not yet recruiting	Neowise Biotechnology	66	2026-10-01	2026-10-15
Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates in Potentially Resectable Locally Advanced Pancreatic Cancer Induction Chemotherapy - FOLFIRINOX, Induction Chemotherapy - Gemcitabine and Nab-Paclitaxel, MR-LINAC Guided Radiotherapy - Pancreatic Cancer	Phase 2	Not yet recruiting	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	20	2026-10-01	2026-10-13

Showing 20 of 1967. Sign in to see all of them.

Narrower conditions

Pancreatic Neoplasms (1967)  ·  Colorectal Neoplasms (225)  ·  Stomach Neoplasms (215)  ·  Breast Neoplasms (183)  ·  Ovarian Neoplasms (152)  ·  Carcinoma, Non-Small-Cell Lung (150)  ·  Lung Neoplasms (140)  ·  Esophageal Neoplasms (137)  ·  Neoplasms (134)  ·  Colonic Neoplasms (124)  ·  Liver Neoplasms (115)  ·  Neoplasm Metastasis (94)  ·  Prostatic Neoplasms (90)  ·  Head and Neck Neoplasms (89)  ·  Melanoma (78)

Broader conditions

Neoplasms by Site (1967)  ·  Digestive System Diseases (1966)  ·  Endocrine System Diseases (1965)  ·  Endocrine Gland Neoplasms (1964)  ·  Digestive System Neoplasms (1962)  ·  Pancreatic Diseases (1947)  ·  Neoplasms (1833)  ·  Gastrointestinal Diseases (427)  ·  Gastrointestinal Neoplasms (381)  ·  Neoplasms by Histologic Type (341)  ·  Intestinal Diseases (323)  ·  Intestinal Neoplasms (319)  ·  Colonic Diseases (295)  ·  Pathological Conditions, Signs and Symptoms (289)  ·  Neoplasms, Glandular and Epithelial (280)

Interventions

Gemcitabine (385)  ·  Fluorouracil (111)  ·  Capecitabine (90)  ·  Oxaliplatin (90)  ·  130-nm albumin-bound paclitaxel (84)  ·  Leucovorin (73)  ·  Radiotherapy (71)  ·  Albumin-Bound Paclitaxel (58)  ·  Irinotecan (57)  ·  Cisplatin (46)  ·  Erlotinib Hydrochloride (46)  ·  Radiosurgery (44)  ·  pembrolizumab (36)  ·  Drug Therapy (34)  ·  Bevacizumab (33)

Sponsors

Memorial Sloan Kettering Cancer Center (43)  ·  M.D. Anderson Cancer Center (37)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (37)  ·  Changhai Hospital (25)  ·  Fudan University (25)  ·  Washington University School of Medicine (24)  ·  H. Lee Moffitt Cancer Center and Research Institute (23)  ·  National Cancer Institute (NCI) (23)  ·  Massachusetts General Hospital (20)  ·  Alliance for Clinical Trials in Oncology (18)  ·  Dana-Farber Cancer Institute (18)  ·  Peking Union Medical College Hospital (18)  ·  IRCCS San Raffaele (17)  ·  Ruijin Hospital (16)  ·  Seoul National University Hospital (16)

Countries

United States (978)  ·  China (321)  ·  France (96)  ·  Italy (93)  ·  South Korea (92)  ·  Canada (87)  ·  United Kingdom (85)  ·  Spain (82)  ·  Germany (71)  ·  Australia (62)  ·  Japan (49)  ·  Netherlands (45)  ·  Belgium (40)  ·  Denmark (37)  ·  Israel (35)

Top investigators

Michele Reni, MD (8)  ·  Andrew Ko, MD (6)  ·  Daniel A. Laheru, MD (6)  ·  Shyam Varadarajulu, MD (6)  ·  Malcolm J. Moore, MD (5)  ·  Mark Zalupski, MD (5)  ·  Nilofer Azad, MD (5)  ·  Pamela Hodul, MD (5)  ·  Steven A Rosenberg, M.D. (5)  ·  Wendy K Chung, MD (5)

Results publications

PMID 39863139, PMID 33337539, PMID 21561347, PMID 15273542, PMID 15908661, PMID 18992248, PMID 21831266, PMID 23229886, PMID 23547081, PMID 24131140, PMID 24840647, PMID 24901360, PMID 26341722, PMID 28040257, PMID 29508247, PMID 29929491, PMID 37069476, PMID 37121331, PMID 37598000, PMID 38050737, PMID 39606939, PMID 39920391, PMID 41486497, PMID 42836590, PMID 10029607, PMID 10400410, PMID 10615932, PMID 10918161, PMID 10924610, PMID 11261621, PMID 11413430, PMID 11815964, PMID 11822956, PMID 11896099, PMID 11910485, PMID 12196376, PMID 12455783, PMID 12649105, PMID 12663718, PMID 12850683, PMID 14556925, PMID 14578723, PMID 14666667, PMID 14758134, PMID 15120036, PMID 15218298, PMID 15317891, PMID 15361643, PMID 15611509, PMID 15646530

NIH funding

P30CA006973 (12), 2016 (7), 2017 (7), P30CA068485 (7), 2015 (6), 2019 (5), 2023 (5), P30CA015083 (5), P30CA016672 (5), P30CA022453 (5), P30CA033572 (5), 2018 (4), P01CA247886 (4), P30CA043703 (4), P30CA072720 (4)